Falsehoods & Facts: The Truth About De Minimis
Background De minimis is a regulatory loophole. It was morphed from a tiny customs administrative exception into a backdoor superhighway through our ports. The regulatory
Venture Capital CEO Tells House Committee He Agrees With Outbound Investment Restrictions
In latest House Select Committee on the CCP, outbound investment restrictions get favorable view.
Candidate Trump Announces Plans to Reshore Essential Medicines to Avoid Drug Shortages
Trump’s call to reshore pharmaceutical production, especially critical medicine in short supply, will set the table for other presidential candidates. Reshoring America’s medicine supply chain is increasingly mainstream, and an easy sell to voters.
FDA Allows Uninspected China Lab to Sell Cancer Drugs in the US
A Chinese cancer drug maker that has not been inspected by the FDA since 2018 is selling chemotherapy drugs to the U.S. due to shortages. When will the U.S. meet its critical medication needs?
To Fight Drug Shortages FDA Has an Idea: Import More Inspection-Free Drugs
The balance between scarcity and supply favors supply, even if that means importing drugs from labs the FDA has not inspected.
Spotlight Shines on CPA in Latest House Ways & Means Trade Hearing
At a recent House Ways & Means subcommittee hearing on trade, CEO Michael Stumo talks de minimis, and the inescapable realities of China’s forced labor.
Written Testimony Before the House Ways & Means Subcommittee on Trade: Modernizing Customs Policies to Protect American Workers and Secure Supply Chains
The following written testimony was submitted by Michael Stumo, CEO of CPA, to the House Ways and Means Subcommittee on Trade for a hearing titled,
House Committee Holds Hearing on Drug Shortages
The U.S. is increasingly reliant on imported drugs from uninspected labs. It’s not safe. What can be done about it?
Written Testimony to the CECC: Implementation of the Uyghur Forced Labor Prevention Act and the Impact on Global Supply Chains
The following written testimony was submitted to the Congressional-Executive Commission China (CECC) on April 18, 2023 by CPA’s Robby Stephany Saunders, Vice President for National
Drug Shortages: Why They Happen, What Can Be Done About Them?
A Senate hearing on pharmaceutical shortages discusses America’s dependence on India and China, and what can be done to reshore.
